Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-21-124600
Filing Date
2021-10-08
Accepted
2021-10-08 16:07:06
Documents
3
Group Members
NOVARTIS AGNOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

Document Format Files

Seq Description Document Type Size
1 SC 13G tm2129445d1_sc13g.htm SC 13G 79619
2 EXHIBIT 99.1 tm2129445d1_ex99-1.htm EX-99.1 37518
3 EXHIBIT 99.2 tm2129445d1_ex99-2.htm EX-99.2 7068
  Complete submission text file 0001104659-21-124600.txt   125910
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Filed by) CIK: 0001030617 (see all company filings)

Type: SC 13G

Mailing Address C/O CORVEX MANAGEMENT LP 667 MADISON AVENUE NEW YORK NY 10065
Business Address C/O CORVEX MANAGEMENT LP 667 MADISON AVENUE NEW YORK NY 10065 (212) 474 6724
SomaLogic, Inc. (Subject) CIK: 0001837412 (see all company filings)

EIN.: 854298912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92455 | Film No.: 211315392
SIC: 8731 Services-Commercial Physical & Biological Research